CMV-β-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1α promoter and results in therapeutic levels of human factor X in mice

Human Gene Therapy

Volumn 12, Issue 5, 2001, Pages 563-573

  Xu, L ^a   Daly, T ^a   Gao, C ^a   Flotte, T R ^b   Song, S ^b   Byrne, B J ^b,c   Sands, M S ^a,d   Ponder, K P ^a,d  

^a 8818 CSRB ^*  (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BLOOD CLOTTING FACTOR 10; ELONGATION FACTOR 1ALPHA; INTERLEUKIN 6; VIRUS VECTOR;

ACUTE PHASE RESPONSE; ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CYTOMEGALOVIRUS; FEMALE; GENE EXPRESSION; GENE INDUCTION; GENE THERAPY; HEMOPHILIA; LIVER; MOUSE; NEWBORN; NONHUMAN; PORTAL VEIN; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ANIMALS; BINDING SITES; BLOTTING, SOUTHERN; CHICKENS; CYTOMEGALOVIRUS; DEPENDOVIRUS; DNA; DNA, COMPLEMENTARY; ENHANCER ELEMENTS (GENETICS); ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR X; FEMALE; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIVER; MICE; MICE, INBRED C57BL; PEPTIDE ELONGATION FACTOR 1; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; TRANSCRIPTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; GALLUS GALLUS;

EID: 0035937316     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401300042500     Document Type: Article

References (52)

1. Activation of the interleukin-2 receptor alpha gene: Regulatory role for DNA-protein interactions flanking the kappa B enhancer
2. Adeno-associated viral vectors for gene transfer and gene therapy
3. Therapeutic levels of functional human protein C in rats after retroviral vector-mediated hepatic gene therapy
4. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity
5. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types
6. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice
7. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
8. Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice
9. Lipopolysaccharide potentiates the effect of hepatocyte growth factor upon hepatocyte replication in rats by augmenting AP-1 DNA binding activity
10. Multiple sequence-specific transcription factors modulate cytomegalovirus enhancer activity in vitro
11. Novel tools for production and purification of recombinant adenoassociated virus vectors
12. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter
13. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs
14. NF-kappaB and the innate immune response
15. Production and purification of recombinant adeno-associated virus
16. Nuclear factor 1 interacts with five DNA elements in the promoter region of the human cytomegalovirus major immediate early gene
17. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
18. Adenovirus-mediated gene therapy of liver diseases
19. In vivo retrovirus-mediated gene transfer to the liver of dogs results in transient expression and induction of a cytotoxic immune response
20. 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes
21. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
22. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter
23. Mechanism of apoptosis suppression by phorbol ester in IL-6-starved murine plasmacytomas: Role of PKC modulation and cell cycle
24. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy
25. Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C protein S, or protein Z
26. Dynamic analysis of proviral induction and de novo methylation: Implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression
27. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFkappaB
28. The kinetics of rAAV integration in the liver
29. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: Cell cycling does not influence hepatocyte transduction
30. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5
31. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver
32. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver
33. Different Sp1 family members differentially affect transcription from the human elongation factor 1 A-1 gene promoter
34. Efficient selection for high-expression transfectants with a novel eukaryotic vector
35. Efficient lentiviral transduction of liver requires cell cycling in vivo
36. Hepatic gene therapy using adeno-associated virus vectors
37. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection
38. Adeno-associated virus 2-mediated gene transfer in vivo: Organ-tropism and expression of transduced sequences in mice
39. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
40. In vivo transduction with retrovirus during in-flow occlusion
41. Liver-directed gene therapy: Quantitative evaluation of promoter elements by using in vivo retroviral transduction
42. Other clotting factor deficiencies
43. Factor X-St. Louis II. Identification of a glycine substitution at residue 7 and characterization of the recombinant protein
44. Percutaneous intravenous injection in neonatal mice
45. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
46. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
47. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors
48. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
49. AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection
50. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha
51. Expression of growth factor ligand and receptor genes in the preimplantation bovine embryo
52. Adeno-associated virus as a vector for liver-directed gene therapy